Vitamin D and Parathyroid Hormone in Kidney Disease

  • Sagar U. NigwekarEmail author


Chronic kidney disease (CKD) is a modern-day epidemic with significant morbidity and mortality. It is well known that CKD is accompanied by reduced conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D and by deficiency of 25-hydroxyvitamin D. These metabolic changes combined with hypocalcemia and hyperphosphatemia lead to secondary hyperparathyroidism, renal osteodystrophy, and vascular calcification. Attempts to prevent this disorder have led to the widespread use of vitamin D receptor agonists and nutritional vitamin D. This is particularly enhanced by the observational data that support the notion that vitamin D treatment may influence survival especially in patients with end-stage renal disease. Furthermore, calcimimetic agents have demonstrated efficacy for reducing parathyroid hormone (PTH) levels without the risk of hypercalcemia or hyperphosphatemia. In this chapter, we discuss the roles of vitamin D and PTH in the CKD population and outline the current state of evidence supporting their therapeutic use.


Calcitriol Chronic kidney disease End-stage renal disease Randomized controlled trials Vitamin D-binding protein 


  1. 1.
    Nwankwo E, Bello AK, El Nahas AM. Chronic kidney disease: stemming the global tide. Am J Kidney Dis. 2005;45(1):201–8.CrossRefGoogle Scholar
  2. 2.
    Moe SM, Radcliffe JS, White KE, et al. The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat. J Bone Miner Res. 2011;26(11):2672–81.CrossRefGoogle Scholar
  3. 3.
    Nigwekar SU, Tamez H, Thadhani RI. Vitamin D and chronic kidney disease-mineral bone disease (CKD-MBD). Bonekey Rep. 2014;3:498.CrossRefGoogle Scholar
  4. 4.
    Larsson TE. The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe? Nephrol Dial Transplant. 2010;25(5):1376–81.CrossRefGoogle Scholar
  5. 5.
    Hruska KA, Choi ET, Memon I, Davis TK, Mathew S. Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD). Pediatr Nephrol. 2010;25(4):769–78.CrossRefGoogle Scholar
  6. 6.
    Nigwekar SU, Bhan I, Thadhani R. Ergocalciferol and cholecalciferol in CKD. Am J Kidney Dis. 2012;60(1):139–56.CrossRefGoogle Scholar
  7. 7.
    Slatopolsky E, Hruska K, Rutherford WE. Current concepts of parathyroid hormone and vitamin D metabolism: perturbations in chronic renal disease. Kidney Int Suppl. 1975;(2):90–6.Google Scholar
  8. 8.
    Holick MF, DeLuca HF. Vitamin D metabolism. Annu Rev Med. 1974;25:349–67.CrossRefGoogle Scholar
  9. 9.
    Nigwekar SU, Thadhani R. Vitamin D receptor activation: cardiovascular and renal implications. Kidney Int Suppl (2011). 2013;3(5):427–30.CrossRefGoogle Scholar
  10. 10.
    Weishaar RE, Simpson RU. Vitamin D3 and cardiovascular function in rats. J Clin Invest. 1987;79(6):1706–12.CrossRefGoogle Scholar
  11. 11.
    Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110(2):229–38.CrossRefGoogle Scholar
  12. 12.
    Bodyak N, Ayus JC, Achinger S, et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A. 2007;104(43):16810–5.CrossRefGoogle Scholar
  13. 13.
    Floege J, Ketteler M. Vascular calcification in patients with end-stage renal disease. Nephrol Dial Transplant. 2004;19(Suppl 5):V59–66.CrossRefGoogle Scholar
  14. 14.
    Moe SM. Vascular calcification: Hardening of the evidence. Kidney Int. 2006;70(9):1535–7.CrossRefGoogle Scholar
  15. 15.
    Nigwekar SU, Bhan I, Turchin A, et al. Statin use and calcific uremic arteriolopathy: a matched case-control study. Am J Nephrol. 2013;37(4):325–32.CrossRefGoogle Scholar
  16. 16.
    Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–81.CrossRefGoogle Scholar
  17. 17.
    Bhan I, Powe CE, Berg AH, et al. Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int. 2012;82(1):84–9.CrossRefGoogle Scholar
  18. 18.
    Powe CE, Evans MK, Wenger J, et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med. 2013;369(21):1991–2000.CrossRefGoogle Scholar
  19. 19.
    Holick MF. Bioavailability of vitamin D and its metabolites in black and white adults. N Engl J Med. 2013;369(21):2047–8.CrossRefGoogle Scholar
  20. 20.
    Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care. 2005;28(5):1228–30.CrossRefGoogle Scholar
  21. 21.
    Liu S, Song Y, Ford ES, Manson JE, Buring JE, Ridker PM. Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care. 2005;28(12):2926–32.CrossRefGoogle Scholar
  22. 22.
    Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab. 2007;92(6):2017–29.CrossRefGoogle Scholar
  23. 23.
    Wolf M, Thadhani R. Vitamin D in patients with renal failure: a summary of observational mortality studies and steps moving forward. J Steroid Biochem Mol Biol. 2007;103(3–5):487–90.CrossRefGoogle Scholar
  24. 24.
    Tamez H, Kalim S, Thadhani RI. Does vitamin D modulate blood pressure? Curr Opin Nephrol Hypertens. 2013;22(2):204–9.CrossRefGoogle Scholar
  25. 25.
    Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72(8):1004–13.CrossRefGoogle Scholar
  26. 26.
    Wolf M, Thadhani R. Beyond minerals and parathyroid hormone: role of active vitamin D in end-stage renal disease. Semin Dial. 2005;18(4):302–6.CrossRefGoogle Scholar
  27. 27.
    Bhan I, Thadhani R. Vitamin D therapy for chronic kidney disease. Semin Nephrol. 2009;29(1):85–93.CrossRefGoogle Scholar
  28. 28.
    Drechsler C, Verduijn M, Pilz S, et al. Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant. 2011;26(3):1024–32.CrossRefGoogle Scholar
  29. 29.
    Thadhani RI, Manson JE. Vitamin D: too soon to turn out the lights? Arterioscler Thromb Vasc Biol. 2013;33(11):2467–9.CrossRefGoogle Scholar
  30. 30.
    Kandula P, Dobre M, Schold JD, Schreiber MJ, Mehrotra R, Navaneethan SD. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 2011;6(1):50–62.CrossRefGoogle Scholar
  31. 31.
    Zhao J, Dong J, Wang H, Shang H, Zhang D, Liao L. Efficacy and safety of vitamin D3 in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials. Chin Med J. 2014;127(15):2837–43.PubMedGoogle Scholar
  32. 32.
    de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010;376(9752):1543–51.CrossRefGoogle Scholar
  33. 33.
    de Borst MH, Hajhosseiny R, Tamez H, Wenger J, Thadhani R, Goldsmith DJ. Active vitamin D treatment for reduction of residual proteinuria: a systematic review. J Am Soc Nephrol. 2013;24(11):1863–71.CrossRefGoogle Scholar
  34. 34.
    Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012;307(7):674–84.CrossRefGoogle Scholar
  35. 35.
    Investigators ET, Chertow GM, Block GA, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482–94.CrossRefGoogle Scholar
  36. 36.
    Lundquist AL, Nigwekar SU. Optimal management of bone mineral disorders in chronic kidney disease and end stage renal disease. Curr Opin Nephrol Hypertens. 2016;25(2):120–6.CrossRefGoogle Scholar
  37. 37.
    Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945–53.CrossRefGoogle Scholar
  38. 38.
    Ketteler M, Elder GJ, Evenepoel P, et al. Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int. 2015;87(3):502–28.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Medicine, Division of NephrologyMassachusetts General HospitalBostonUSA

Personalised recommendations